(1) Upon providing notice on the centralized, internet-based communication tool required by RCW 70.14.100 (1)(b) that the health technology has been selected for review, the director shall post an invitation for interested parties to submit information relevant to the health technology for consideration by the evidence-based technology assessment center. The information must be submitted to the director or designee within thirty calendar days from the date of the notice.

(2) Upon notice of the health technology selected for review, the director or designee shall request participating agencies to provide information relevant to the health technology, including data on safety, health outcome, and cost. The relevant information must be submitted to the director or designee within thirty calendar days from the date of the notice.

(3) Upon notice of the health technology selected for review, the director or designee shall identify relevant decisions made under the federal medicare program and expert treatment guidelines, including those from specialty physician and patient advocacy organizations, and any referenced information used as the basis for such determinations or guidelines.

(4) The director shall provide all information gathered under subsections (1), (2), and (3) of this section to the evidence-based technology assessment center and shall post such information, along with the key questions for review, on the centralized, internet-based communication tool.

(5) Upon completion of the health technology assessment by the evidence-based technology assessment center, the director shall publish a copy of the health technology assessment on the centralized, internet-based communication tool and provide the committee with:

(a) A copy of the health technology assessment;

(b) A copy of decisions made under the federal medicare program related to the health technology being reviewed and accompanying information describing the basis for the decision;

(c) Information as to whether expert treatment guidelines exist, including those from specialty physician organizations and patient advocacy organizations, and describing the basis for the guidelines.